News & Insights

As evidence teams plan for 2026, expectations in rare diseases are shifting towards evidence that is carefully contextualised and clearly linked to decision-making needs. Recent guidance and industry commentary highlight the growing role of patient experience data, integrated real-world evidence, and earlier cross-functional planning, reinforcing that credibility comes from clarity and relevance rather than scale or complexity alone.

DHT.health launch Evidence and Insights programmes, a multi-country initiative built to capture patient voice, lived experience and outcomes in rare and underserved diseases.

DHT.health recognised among Grant Thornton’s Top 100 “Ones to Watch” in the UK Pharma Services Sector

Inherited bleeding disorders (iBDs), such as haemophilia A and B, von Willebrand disease (VWD), and Glanzmann thrombasthenia, present unique challenges for health technology assessment (HTA). Treatments are often lifelong, costly, and evolving rapidly, especially with the advent of gene therapies and non-factor replacement options like emicizumab. Economic evaluations (EEs) are essential to guide reimbursement and policy decisions, and modelling plays a central role in these

Patient Reported Outcomes in understanding lived experiences of individuals with a health condition.

In the rapidly evolving landscape of healthcare, patient-centricity is more than just a buzzword—it's becoming the cornerstone of...

How can remote data collection methods be used in rare disease research?

Ultra-Rare Disease. Unique challenge and future directions for HEOR in ultra-rare disease.

Rare diseases are estimated to impact around 300 million people globally. The burden of rare diseases presents a global challenge by...